B. F. Palmer, Managing hyperkalemia caused by inhibitors of the renin-angiotensinaldosterone system, N Engl J Med, vol.351, issue.6, pp.585-92, 2004.

P. Ponikowski, A. A. Voors, S. D. Anker, H. Bueno, J. G. Cleland et al., ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC), Eur J Heart Fail, 2016.

C. W. Yancy, M. Jessup, B. Bozkurt, J. Butler, D. E. Casey et al., ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America, J Am Coll Cardiol, 2016.

F. Zannad, J. P. Ferreira, and B. Pitt, Potassium binders for the prevention of hyperkalaemia in heart failure patients: implementation issues and future developments, Eur Heart J Suppl, vol.21, pp.55-60, 2019.

A. J. Collins, B. Pitt, N. Reaven, S. Funk, K. Mcgaughey et al., Association of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and/or Diabetes, Am J Nephrol, vol.46, issue.3, pp.213-221, 2017.

M. L. Krogager, C. Torp-pedersen, R. N. Mortensen, L. Kober, G. Gislason et al., Short-term mortality risk of serum potassium levels in hypertension: a retrospective analysis of nationwide registry data, Eur Heart J, 2016.

A. Goyal, J. A. Spertus, K. Gosch, L. Venkitachalam, P. G. Jones et al., Serum potassium levels and mortality in acute myocardial infarction, JAMA, vol.2012, issue.2, pp.157-64

B. Pitt and P. Rossignol, Serum potassium in patients with chronic heart failure: once we make a U-turn where should we go?, Eur Heart J, vol.2017, issue.38, pp.2897-2899

C. P. Kovesdy, K. Matsushita, Y. Sang, N. J. Brunskill, J. J. Carrero et al., Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis

, Eur Heart J, 2018.

J. Hayes, K. Kalantar-zadeh, J. L. Lu, S. Turban, J. E. Anderson et al., Association of hypo-and hyperkalemia with disease progression and mortality in males with chronic kidney disease: the role of race, Potassium Fluctuations Are Associated With Inhospital Mortality From Acute Myocardial Infarction. Soroka Acute Myocardial Infarction II, vol.2012, pp.709-717, 2018.

C. P. Kovesdy, L. J. Appel, M. E. Grams, L. Gutekunst, P. A. Mccullough et al., Potassium homeostasis in health and disease: A scientific workshop cosponsored by the National Kidney Foundation and the American Society of Hypertension, J Am Soc Hypertens, vol.2017, issue.12, pp.783-800

J. J. Mcmurray, M. Packer, A. S. Desai, J. Gong, M. P. Lefkowitz et al., Angiotensin-neprilysin inhibition versus enalapril in heart failure, N Engl J Med, vol.371, issue.11, pp.993-1004, 2014.

J. Mcmurray, W. J. Coutie, L. Mcfarlane, and A. D. Struthers, Atrial natriuretic factor inhibits ACTH stimulated aldosterone, but not cortisol, secretion in man, Eur J Clin Pharmacol, vol.35, issue.4, pp.409-421, 1988.

J. V. Anderson, A. D. Struthers, N. N. Payne, J. D. Slater, and S. R. Bloom, Atrial natriuretic peptide inhibits the aldosterone response to angiotensin II in man, Clin Sci, vol.70, issue.5, pp.507-519, 1986.

F. Harrell, Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis, 2001.

S. Haneuse, T. J. Vanderweele, and D. Arterburn, Using the E-Value to Assess the Potential Effect of Unmeasured Confounding in Observational Studies, Jama, vol.2019, issue.6, pp.602-603

M. Aldahl, A. C. Jensen, L. Davidsen, M. A. Eriksen, S. Moller-hansen et al., Associations of serum potassium levels with mortality in chronic heart failure patients, Eur Heart J, vol.2017, issue.38, pp.2890-2896

J. Nunez, A. Bayes-genis, F. Zannad, P. Rossignol, E. Nunez et al., Long-Term Potassium Monitoring and Dynamics in Heart Failure and Risk of Mortality, Circulation, vol.2018, issue.13, pp.1320-1330

G. Savarese, H. Xu, M. Trevisan, U. Dahlstrom, P. Rossignol et al., Incidence, Predictors, and Outcome Associations of Dyskalemia in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction, JACC Heart Fail, vol.7, issue.1, pp.65-76, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02510424

J. P. Ferreira, Abnormalities of Potassium in Heart Failure, JACC, 2020.

L. B. Cooper, L. Benson, R. J. Mentz, G. Savarese, A. D. Devore et al., Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry, Eur J Heart Fail, 2020.

P. Rossignol, M. Lainscak, M. G. Crespo-leiro, C. Laroche, M. F. Piepoli et al., Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry, Prog Cardiovasc Dis, vol.24, issue.5, pp.387-418, 1966.

J. E. Macdonald and A. D. Struthers, What is the optimal serum potassium level in cardiovascular patients?, J Am Coll Cardiol, vol.43, issue.2, pp.155-61, 2004.

J. N. Weiss, Z. Qu, and K. Shivkumar, Electrophysiology of Hypokalemia and Hyperkalemia, Circ Arrhythm Electrophysiol, vol.10, issue.3, 2017.

P. Rossignol, N. Girerd, G. Bakris, O. Vardeny, B. Claggett et al., Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia, Eur J Heart Fail, vol.19, issue.6, pp.792-799, 2017.

S. L. Kristensen, F. Martinez, P. S. Jhund, J. L. Arango, J. Belohlavek et al., Geographic variations in the PARADIGM-HF heart failure trial, Eur Heart J, vol.37, issue.41, pp.3167-3174, 2016.

M. Vaduganathan, B. L. Claggett, P. S. Jhund, J. W. Cunningham, J. Ferreira et al., Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials, Lancet, vol.2020, pp.121-128, 10244.
URL : https://hal.archives-ouvertes.fr/hal-02863402

A. S. Desai, O. Vardeny, B. Claggett, J. J. Mcmurray, M. Packer et al., Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial, JAMA Cardiol, vol.2017, issue.1, pp.79-85

N. T. Median, BNP in AF+, vol.3019, p.2131, 1561.

N. Median and . Bnp, 2424) <0.001 NYHA functional class, n. (%) I 6 (3.7%), vol.747, p.306

, Hypertension

N. Diabetes, , p.54

. Atrial-fibrillation, , p.60

N. Prior-hf-hospitalization, , p.119

M. I. Prior, , p.61

, Prior use of ACEi, n. (%), p.115

. Prior and N. Arb, , p.51

N. Diuretic, , p.141

N. Digoxin, %) 50 (30.5%)

N. Beta-blocker, , p.154

N. Mra, , p.75

. Icd-(incl and N. Crt-d), , p.18

R. , Sacubitril/Valsartan, vol.84

, Legend: eGFR, estimated glomerular filtration rate

H. Hf and . Failure,

. Mi,

, ACEi, angiotensin-converting enzyme inhibitor

. Arb and . Blocker,

, MRA, mineralocorticoid receptor antagonist

, ICD, intra-cardiac defibrillator; CRT, cardiac resynchronization therapy

. Af,